New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
December 5, 2017 – Novo Nordisk announced the FDA approval of Ozempic (semaglutide), as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).
Download PDF
Return to publications
